Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Caterpillar reported FY2025 revenue of $67.6 billion, FY2025 operating income of $11.2 billion and Q1 2026 revenue of $17.4 billion. The thesis is dealer-network strength, margin durability and cash generation through an industrial cycle.
Tag facets appear after tag usage counts are rebuilt.
QuantumScape reported no revenue in FY2025 or Q1 2026, a FY2025 net loss of $435.1 million and Q1 2026 operating cash use of $59.5 million. The thesis depends on technology milestones, partner validation, manufacturing scale-up, cash runway and dilution contro
OpenGE Vernova reported FY2025 revenue of $38.1 billion, FY2025 operating income of $1.4 billion, FY2025 operating cash flow of $5.0 billion and Q1 2026 revenue of $9.3 billion. The setup depends on grid demand, power-equipment execution, contract liabilities, mar
OpenDeere reported FY2025 revenue of $45.7 billion and Q1 2026 revenue of $9.6 billion. The thesis depends on farm-cycle demand, precision technology, dealer discipline, margins and financing credit quality.
OpenAgenus has pushed BOT plus BAL into a global Phase 3 colorectal cancer trial and is generating early access revenue, but the current thesis is a race between regulatory progress and financing pressure: Q1 cash was $35.0M, operating cash flow was negative, the
OpenSenmiao Technology is a very high risk China ride-hailing auto-services microcap. The filings show a small post-disposal operating base, continuing losses, material weaknesses, Nasdaq compliance pressure and potentially heavy dilution mechanics.
OpenAgroz has a real Malaysian CEA business and fast disclosed H1 2025 revenue growth, but AGRZ is a limited-disclosure microcap until it files FY2025 annual results, collects receivables and proves cash conversion.
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenAGCO is a global farm-equipment maker with Fendt, Massey Ferguson, PTx and Valtra, but the current thesis is a cycle and execution test: FY2025 sales fell 13.5%, Q1 2026 sales rebounded 14.3%, Europe carried segment profit, and PTx precision agriculture must p
OpenAllied still has HyperX Arena Las Vegas, Z-Tech mobile games, and a balance-sheet cushion, but the current thesis is about the late 10-K, Nasdaq delisting risk, reverse-split vote, Knighted settlement, and whether revenue can ever catch the cost base.
OpenFirst Majestic is producing real cash in a high silver and gold price tape. The decision point is whether costs, Mexico tax risk, resource conversion and Jerritt Canyon restart spending leave enough of that cash for shareholders.
OpenAEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenAnfield Energy's updated PEA makes the Shootaring mill restart look explosive, but AEC is still a no-revenue uranium developer that has to clear permits, capital, reserves, construction, and first production.
OpenAebi Schmidt is a newly enlarged specialty-vehicle platform with snowplows, municipal equipment, airport equipment, commercial truck bodies, Shyft merger synergies, a $1.3 billion backlog, and a leverage target that needs cash conversion.
OpenAddex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenAdient has the footprint OEMs need and the revenue scale investors notice, but the stock case comes down to whether EMEA repair, Asia pricing, launch costs, tariffs, and working capital finally let margin catch up with sales.
OpenADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.
OpenSigned-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.